Incyte Corp (INCY)

Feb 21, 2025

Lobbying Update: $350,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq

Feb 21, 2025

Feb 21, 2025

Incyte Corp. partners with Genesis Therapeutics to use AI for drug discovery - The Business Journals

Feb 21, 2025

Feb 21, 2025

Incyte and Genesis go boldly into AI-focused research - The Pharma Letter

Feb 21, 2025

Feb 20, 2025

Incyte joins the group getting guidance from AI’s Genesis - BioWorld Online

Feb 20, 2025

Feb 20, 2025

Incyte Secures Exclusive Rights In $30Mln AI Collaboration With Genesis Therapeutics - Nasdaq

Feb 20, 2025

Feb 20, 2025

Incyte partners with Genesis to discover new small molecule drugs - Investing.com

Feb 20, 2025

Feb 20, 2025

AI Meets Drug Discovery: Inside Incyte's $620M Genesis DealWill This Transform Pharma R&D? - StockTitan

Feb 20, 2025

Feb 19, 2025

Incyte to Present at Upcoming March 2025 Investor Conferences - BioSpace

Feb 19, 2025

Feb 18, 2025

Exclusive Healthcare Investor Access: Incyte's Double Conference Reveal Coming in March - StockTitan

Feb 18, 2025

Feb 18, 2025

Are Wall Street Analysts Bullish On Incyte Stock? - Barchart

Feb 18, 2025

Feb 18, 2025

Incyte's SWOT analysis: stock prospects amid patent cliff and pipeline potential - Investing.com

Feb 18, 2025

Feb 18, 2025

Are Wall Street Analysts Bullish on Incyte Stock? - Nasdaq

Feb 18, 2025

Feb 17, 2025

Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN

Feb 17, 2025

Feb 16, 2025

Incyte jumps amid takeover speculation - MSN

Feb 16, 2025

Feb 15, 2025

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN

Feb 15, 2025

Feb 15, 2025

Incyte (NASDAQ:INCY) Stock Rating Lowered by StockNews.com - MarketBeat

Feb 15, 2025

Feb 15, 2025

Incyte (NASDAQ:INCY) Price Target Raised to $77.00 at Stifel Nicolaus - MarketBeat

Feb 15, 2025

Feb 14, 2025

Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions - MSN

Feb 14, 2025

Feb 14, 2025

abrdn plc Cuts Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Feb 14, 2025

Feb 14, 2025

Incyte (NASDAQ:INCY) Trading Down 8.5% Following Weak Earnings - MarketBeat

Feb 14, 2025

Feb 14, 2025

State of Alaska Department of Revenue Has $1.26 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat

Feb 14, 2025

Feb 14, 2025

Citigroup Issues Pessimistic Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat

Feb 14, 2025

Feb 13, 2025

Stifel raises Incyte stock price target to $77 from $75 - MSN

Feb 13, 2025

Feb 13, 2025

Sumitomo Mitsui Trust Group Inc. Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Feb 13, 2025

Feb 13, 2025

Incyte (NASDAQ:INCY) Issues Earnings Results - MarketBeat

Feb 13, 2025

Feb 13, 2025

Incyte stock falls 6% amid Q4 earnings, 2025 forecast - MSN

Feb 13, 2025

Feb 13, 2025

Incyte stock price target raised to $88 at TD Cowen - MSN

Feb 13, 2025

Feb 13, 2025

Cambiar Investors LLC Has $9.65 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat

Feb 13, 2025

Feb 12, 2025

JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating -February 12, 2025 at 10:29 am EST - Marketscreener.com

Feb 12, 2025

Feb 12, 2025

Incyte backs out of immuno-oncology pact with Agenus - PharmaLive

Feb 12, 2025

Feb 12, 2025

Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha

Feb 12, 2025

Feb 12, 2025

Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace

Feb 12, 2025

Feb 12, 2025

Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus.com

Feb 12, 2025

Feb 11, 2025

Incyte Earnings: Strong Opzelura Sales; Focus on Expanding Portfolio Amid Jakafi Patent Expiration - Morningstar

Feb 11, 2025

Feb 11, 2025

Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None - Morningstar

Feb 11, 2025

Feb 11, 2025

Incyte's Revenue Beats Estimates Thanks To Jakafi And Opzelura - Finimize

Feb 11, 2025

Feb 11, 2025

Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN

Feb 11, 2025

Feb 11, 2025

Incyte (INCY) Stock Drops Amid Slower Growth Outlook - GuruFocus.com

Feb 11, 2025

Feb 11, 2025

Royal Bank of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price - MarketBeat

Feb 11, 2025

Feb 11, 2025

RBC cuts Incyte stock price target to $68 from $70 - Investing.com

Feb 11, 2025

Feb 11, 2025

Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 11, 2025

Feb 11, 2025

What Analysts Are Saying About Incyte Stock - Benzinga

Feb 11, 2025

Feb 11, 2025

Citi cuts Incyte stock price target to $88, maintains buy rating - MSN

Feb 11, 2025

Feb 11, 2025

Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating -February 11, 2025 at 07:18 am EST - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Feb 11, 2025

Feb 11, 2025

Incyte’s Strong 2024 Financial Performance and Promising Outlook - MSN

Feb 11, 2025

Feb 11, 2025

Applovin, Incyte, Onsemi - TradingView

Feb 11, 2025

Feb 11, 2025

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - Yahoo Finance

Feb 11, 2025

Feb 11, 2025

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook By GuruFocus - Investing.com Canada

Feb 11, 2025

Feb 11, 2025

Why Incyte (INCY) Shares Are Plunging Today - The Globe and Mail

Feb 11, 2025

Feb 11, 2025

Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN

Feb 11, 2025

Feb 11, 2025

Incyte: Q4 Earnings Snapshot - mySA

Feb 11, 2025